Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney Transplant.

ABSTRACT:

Background

Standard-of-care biomarkers for renal allograft rejection are lagging indicators, signaling existing organ injury. This precludes early intervention, when immunological cascades leading to rejection are most susceptible. Donor-derived cell-free DNA (dd-cfDNA) shows promise as an early indicator of rejection, allowing earlier and possibly more effective treatment. This analysis was designed to assess this promise using real-world dd-cfDNA testing evidence.

Methods

This retrospective analysis of the prospective, observational ProActive registry study (NCT04091984) assessed dd-cfDNA and serum creatinine levels before biopsy in 424 patients with ≥1 dd-cfDNA test (n = 1013) in the 6 mo before biopsy.

Results

Of 4667 enrolled patients, 1631 patients had ≥18 mo of

SUBMITTER: Bromberg JS 

PROVIDER: S-EPMC11335081 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature